Urate Oxidase (Uricase)

11/01/2015 - "The yeast extract and uricase inhibition method were used to build hyperuricemia model, and the corresponding drugs were administrated on the 7th day. "
06/10/2015 - "Urate oxidase (Uox), a therapeutic enzyme for treatment of hyperuricemia, is a homotetramer with multiple surface lysines, limiting conventional approaches for albumination. "
01/01/2015 - "Urate oxidase is considered as an important therapeutic enzyme used to control hyperuricemia. "
01/01/2012 - "The effect of hyperuricemia induced by uricase inhibition in rats on renal mitochondrial integrity was also assessed. "
01/01/2012 - "Uricase has proven therapeutic value in treating hyperuricemia but sufficient reduction of its immunogenicity may be the largest obstacle to its chronic use. "

10/01/2007 - "Learning how and when to employ uricase as bridge therapy in refractory gout."
06/01/2007 - "Uricase and other novel agents for the management of patients with treatment-failure gout."
03/01/2007 - "Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout."
06/01/2003 - "The case for uricase in gout."
05/01/1995 - "Urate-oxidase therapy should be viewed as a phase in the treatment of gout, which must be followed by administration of another agent."

05/01/2014 - "Twenty-one patients with hematologic malignancies in complete remission undergoing myeloablative peripheral blood HSCT received recombinant urate oxidase at .20 mg/kg for 5 consecutive days during conditioning. "
04/01/2006 - "To confirm the efficacy of recombinant urate oxidase (rasburicase) and its safety profile, a phase IV compassionate use prospective study was performed in Korean pediatric patients with hematologic malignancies. "
12/01/2003 - "Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome."
04/01/2008 - "Rasburicase (Fasturtec), a recombinant urate oxidase, is highly effective in preventing and treating hyperuricemia in children with hematologic malignancies. "
01/01/2008 - "Recently, rasburicase, a recombinant urate oxidase, has been developed for the treatment of hyperuricemia in patients with primarily hematological malignancies. "

10/01/2004 - "Tumor lysis syndrome (TLS) occurred in 9% during induction phase with a high mortality of 44% (urate-oxidase was available only at the end of the study). "
01/01/2014 - "Urate oxidase should remain mandatory in patients at high risk of tumor lysis syndrome."
08/01/2007 - "Avoiding dialysis in tumour lysis syndrome: is urate oxidase effective? "
07/01/1998 - "Prophylactic use of urate-oxidase in all patients with advanced stage NHL might limit the incidence of tumor lysis syndrome. "
01/01/1985 - "Urate-oxidase as hypouricemic agent in a case of acute tumor lysis syndrome."

04/01/1976 - "[Influence of renal insufficiency on the pharmokinetics and metabolism of urate oxidase]."
04/01/2009 - "The patient underwent acute oliguric renal failure, which required treatment with hyperhydration, urine alkalinization, urate oxidase and hemodialysis, with a fatal evolution.In"
07/01/2005 - "Hyperhydration, urine alkalinization, urate oxidase administration and continuous veno-venous haemodiafiltration (CVVHDF) permitted to control the initial renal failure and to administer chemotherapy. "
04/01/1985 - "Prevention of hyperuricemia and of secondary renal failure is now possible with urate oxidase, allowing an aggressive and rapid induction. "
01/01/2010 - "Although urate oxidase might be effective in reducing serum uric acid, it is still unclear whether this translates into a reduction in mortality or renal failure. "